Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia

被引:220
作者
Garcia, JM
Garcia-Touza, M
Hijazi, RA
Taffet, G
Epner, D
Mann, D
Smith, RG
Cunningham, GR
Marcelli, M
机构
[1] Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Med, Div Endocrinol Diabet & Metab, Houston, TX 77030 USA
[3] Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA
关键词
D O I
10.1210/jc.2004-1788
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Anorexia and weight loss are negative prognostic factors in patients with cancer. Although total ghrelin levels are increased in energy-negative states, levels of the biologically active octanoylated ghrelin and the anorexigenic peptide YY (PYY) have not been reported in patients with cancer-induced cachexia. We hypothesized that abnormal ghrelin and/or PYY levels contribute to cancer-induced cachexia. We evaluated 21 patients with cancer-induced cachexia; 24 cancer patients without cachexia; and 23 age-, sex-, race-, and BMI-matched subjects without cancer. Active ghrelin levels and the active to total ghrelin ratio were significantly increased in subjects with cancer-induced cachexia, compared with cancer and noncancer controls. PYY levels were similar among groups. Appetite measured by a visual analog scale was not increased in subjects with cachexia. The increase in active ghrelin levels is likely to be a compensatory response to weight loss. Cachexia may be a state of ghrelin resistance because appetite does not correlate with ghrelin levels. Changes in the active to total ghrelin ratio suggest that a mechanism other than increased secretion must be responsible for the increase in active ghrelin levels. PYY is unlikely to play an important role in cancer-induced cachexia.
引用
收藏
页码:2920 / 2926
页数:7
相关论文
共 52 条
[1]   Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin [J].
Asakawa, A ;
Inui, A ;
Kaga, T ;
Yuzuriha, H ;
Nagata, T ;
Ueno, N ;
Makino, S ;
Fujimiya, M ;
Niijima, A ;
Fujino, MA ;
Kasuga, M .
GASTROENTEROLOGY, 2001, 120 (02) :337-345
[2]   Gut hormone PYY3-36 physiologically inhibits food intake [J].
Batterham, RL ;
Cowley, MA ;
Small, CJ ;
Herzog, H ;
Cohen, MA ;
Dakin, CL ;
Wren, AM ;
Brynes, AE ;
Low, MJ ;
Ghatei, MA ;
Cone, RD ;
Bloom, SR .
NATURE, 2002, 418 (6898) :650-654
[3]   Inhibition of food intake in obese subjects by peptide YY3-36 [J].
Batterham, RL ;
Cohen, MA ;
Ellis, SM ;
Le Roux, CW ;
Withers, DJ ;
Frost, GS ;
Ghatei, MA ;
Bloom, SR .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (10) :941-948
[4]   Non-acylated ghrelin does not possess the pituitaric and pancreatic endocrine activity of acylated ghrelin in humans [J].
Broglio, F ;
Benso, A ;
Gottero, C ;
Prodarn, F ;
Gauna, C ;
Filtri, L ;
Arvat, E ;
van der Lely, AJ ;
Deghenghi, R ;
Ghigo, E .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2003, 26 (03) :192-196
[5]  
Bruera E, 1991, J Palliat Care, V7, P6
[6]   Acute effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouse [J].
Challis, BG ;
Pinnock, SB ;
Coll, AP ;
Carter, RN ;
Dickson, SL ;
O'Rahilly, S .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 311 (04) :915-919
[7]  
Chang VT, 2000, CANCER, V88, P2164, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2164::AID-CNCR24>3.0.CO
[8]  
2-5
[9]   COMPARTMENTAL BODY-COMPOSITION OF CANCER-PATIENTS BY MEASUREMENT OF TOTAL-BODY NITROGEN, POTASSIUM, AND WATER [J].
COHN, SH ;
GARTENHAUS, W ;
SAWITSKY, A ;
RAI, K ;
ZANZI, I ;
VASWANI, A ;
ELLIS, KJ ;
YASUMURA, S ;
CORTES, E ;
VARTSKY, D .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1981, 30 (03) :222-229
[10]   What is the role of the insulin-like growth factor system in the pathophysiology of cancer cachexia, and how is it regulated? [J].
Crown, AL ;
Cottle, K ;
Lightman, SL ;
Falk, S ;
Mohamed-Ali, V ;
Armstrong, L ;
Millar, AB ;
Holly, JMP .
CLINICAL ENDOCRINOLOGY, 2002, 56 (06) :723-733